ISDA

Entry Detail

PDB ID:

6XKP

Keywords:

VIRAL PROTEIN/IMMUNE SYSTEM

Title:

Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-270

Biological Source:

Source Organism:

Severe acute respiratory syndrome coronavirus 2, Homo sapiens

Host Organism:

Trichoplusia ni

PDB Version:

Deposition Date:

2020-06-26

Release Date:

2020-10-14

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.72 Å

R-Value Free:

0.26

R-Value Work:

0.21

R-Value Observed:

0.22

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Spike protein S1
Chain IDs:A, B
Chain Length:231
Number of Molecules:2
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTC2 Pfam ID:PF09408

Polymer Type:polypeptide(L)
Description:CV07-270 Heavy Chain
Chain IDs:C (auth: H), E (auth: M)
Chain Length:232
Number of Molecules:2
Biological Source:Homo sapiens

Polymer Type:polypeptide(L)
Description:CV07-270 Light Chain
Chain IDs:D (auth: L), F (auth: N)
Chain Length:216
Number of Molecules:2
Biological Source:Homo sapiens

Ligand Molecules

NAG

SO4

Primary Citation

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.

Kreye, J, Reincke, S.M, Kornau, H.C, Sanchez-Sendin, E, Corman, V.M, Liu, H, Yuan, M, Wu, N.C, Zhu, X, Lee, C.D, Trimpert, J, Holtje, M, Dietert, K, Stoffler, L, von Wardenburg, N, van Hoof, S, Homeyer, M.A, Hoffmann, J, Abdelgawad, A, Gruber, A.D, Bertzbach, L.D, Vladimirova, D, Li, L.Y, Barthel, P.C, Skriner, K, Hocke, A.C, Hippenstiel, S, Witzenrath, M, Suttorp, N, Kurth, F, Franke, C, Endres, M, Schmitz, D, Jeworowski, L.M, Richter, A, Schmidt, M.L, Schwarz, T, Muller, M.A, Drosten, C, Wendisch, D, Sander, L.E, Osterrieder, N, Wilson, I.A, Pruss, H.Show

Cell 183 1058 ? (2020)

PMID: 33058755 DOI: 10.1016/j.cell.2020.09.049

Abstact

The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from 10 COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb, CV07-209, neutralized authentic SARS-CoV-2 with an IC50 value of 3.1 ng/mL. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2-neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss, and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy.

Legend

Protein

Chemical

Disease

Primary Citation of related structures